Product Introduction
Bioactivity


英文名: Cyclo(Phe-Gly)

描述: Cyclo(Phe-Gly) shows weak antagonistic activity against VEGFR2 -CD, it also shows strong inhibitory activity against human cancer cells(KB,KBv200) with LD50 at 6.5 and 11.2 umol/L,respectively.

體外活性: To discover antagonists of VEGFR2-CD from the fermentation broth produced by streptomyces strain I06A-02832. METHODS AND RESULTS:Under the guidance of ELISA assay against VEGFR2-CD, Compounds 2832 B and 2832 C were isolated and purified by combination of different column chromatographies and HPLC. The structures of compounds 2832 B and C were identified by combination of analysis of UV, IR, MS and 1D-NMR, 2D-NMR. Compounds 2832 B and 2832 C were purified and structurally identified as cyclic dipeptides, and were the same with cyclo-(Pro-Tyr) and Cyclo(Phe-Gly) respectively. Compounds 2832 B and 2832 C showed weak antagonistic activity against VEGFR2-CD by ELISA assay. CONCLUSIONS: They are firstly reported compounds 2832 B and 2832 C had antagonistic activity against VEGFR2-CD.

存儲條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

關鍵字: Cyclo(Phe Gly) | Cyclo(Phe-Gly) | Cyclo(PheGly)

TargetMol（陶術）作為一家全球性的生物醫藥領域高科技企業，我們致力于為高校、研究所、醫院、企業等各類生物醫藥研發機構提供優質的產品和服務，為全球醫藥科學家更高效地完成科研工作助力�？商峁�20,000+種 抑制劑和激動劑 、800+種 化合物庫 、19,000+種 天然產物 ，以及9,000+種 重組蛋白 、多種 多肽 、抗體 和 生命科學試劑盒 等。此外，在上海，TargetMol研發中心配備了 CADD & AIDD研究中心、藥理實驗室和藥物化學合成 平臺三大技術中心，可提供虛擬篩選、化合物活性測試、分子間結合力檢測和化合物結構優化等技術服務，多方位滿足用戶的研發需求。